Prezista 600 mg Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Prezista 600 mg Tablet contains darunavir, an HIV-1 protease inhibitor. It is prescribed for the treatment of HIV-1 infection in adults, generally together with low-dose ritonavir and other antiretroviral agents, at the dose and duration set by the prescriber.

Active ingredient
Darunavir
Strength
600 mg
Dosage form
Oral tablet
Therapeutic class
HIV-1 protease inhibitor
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with darunavir and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Treatment of HIV-1 infection in adult patients
  • Used with other antiretroviral agents and boosted with low-dose ritonavir, per prescribing information
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Taken orally at the dose and duration prescribed; the full medication course should be completed
  • Co-administered with ritonavir and taken with food, per prescribing information
  • Doses should not be skipped, to maintain effective drug levels

Described Side Effects

Commonly described side effects include:

  • Diarrhoea and nausea
  • Rash
  • Headache
  • Abdominal pain

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Complete medical history, including any sulfonamide allergy and liver disease, should be shared with the prescriber
  • Darunavir has significant drug interactions; all current medicines should be disclosed
  • Pregnancy or breastfeeding should be discussed with the prescriber
  • Any persistent or severe side effects should be reviewed by a clinician

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, it contains darunavir, an HIV-1 protease inhibitor used in adults within combination antiretroviral therapy, boosted with ritonavir. SDO Pharma has not independently verified these claims.

Per prescribing information, darunavir is co-administered with low-dose ritonavir and other antiretroviral agents, and taken with food.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services